Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Wanbang

<< Previous

Bullboard Posts

Next >>

Comment by bazooka73on Mar 11, 2021 12:10am

178 Views

Post# 32769849

RE:RE:RE:RE:RE:Wanbang

JL202101 wrote: The one that was approved for Wanbang is the generic drug of Empagliflozin. The patent of Empagliflozin was invalid in China, and a few pharmacy have been approved for the generic drug of Empagliflozin.

So I wonder if that will have an impact on Sirona's SGLT2 inhibitor and/or the ongoing development by Wanbang. And if so, what would that mean?

<< Previous

Bullboard Posts

Next >>

AI companies to invest in